Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Merck & Co Inc’s stock clocked out at $77.6, down -2.60% from its previous closing price of $79.67. In other words, the price has decreased by -$2.60 from its previous closing price. On the day, 14.84 million shares were traded. MRK stock price reached its highest trading level at $79.875 during the session, while it also had its lowest trading level at $77.58.
Ratios:
To gain a deeper understanding of MRK’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 22.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.17. For the most recent quarter (mrq), Quick Ratio is recorded 1.17 and its Current Ratio is at 1.42. In the meantime, Its Debt-to-Equity ratio is 0.72 whereas as Long-Term Debt/Eq ratio is at 0.69.
On May 14, 2025, Citigroup Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $84.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $85.Cantor Fitzgerald initiated its Neutral rating on April 22, 2025, with a $85 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 25 ’25 when Smart Dalton E. III sold 4,262 shares for $82.76 per share. The transaction valued at 352,723 led to the insider holds 7,778 shares of the business.
DALTON SMART bought 4,262 shares of MRK for $352,723 on Apr 25 ’25. On Feb 19 ’25, another insider, Oosthuizen Johannes Jacobus, who serves as the President, U.S. Market of the company, sold 8,500 shares for $84.09 each. As a result, the insider received 714,745 and left with 30,705 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRK now has a Market Capitalization of 193827979264 and an Enterprise Value of 220674981888. As of this moment, Merck’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.96, and their Forward P/E ratio for the next fiscal year is 8.05. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.07. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.06 while its Price-to-Book (P/B) ratio in mrq is 3.96. Its current Enterprise Value per Revenue stands at 3.469 whereas that against EBITDA is 7.789.
Stock Price History:
The Beta on a monthly basis for MRK is 0.37, which has changed by -0.31744218 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, MRK has reached a high of $116.02, while it has fallen to a 52-week low of $73.31. The 50-Day Moving Average of the stock is -5.92%, while the 200-Day Moving Average is calculated to be -10.10%.
Shares Statistics:
It appears that MRK traded 13.11M shares on average per day over the past three months and 13078600 shares per day over the past ten days. A total of 2.50B shares are outstanding, with a floating share count of 2.50B. Insiders hold about 0.10% of the company’s shares, while institutions hold 80.14% stake in the company. Shares short for MRK as of 1757894400 were 27709865 with a Short Ratio of 2.11, compared to 1755216000 on 25529478. Therefore, it implies a Short% of Shares Outstanding of 27709865 and a Short% of Float of 1.24.
Dividends & Splits
With its trailing 12-month dividend rate of 3.16, MRK has a forward annual dividend rate of 3.24. Against a Trailing Annual Dividend Yield of 0.039663613. The stock’s 5-year Average Dividend Yield is 3.02. The current Payout Ratio is 46.32% for MRK, which recently paid a dividend on 2025-09-15 with an ex-dividend date of 2025-09-15. Stock splits for the company last occurred on 2021-06-03 when the company split stock in a 1048:1000 ratio.
Earnings Estimates
The firm’s stock currently is rated by 14.0 analysts. The consensus estimate for the next quarter is $2.2, with high estimates of $2.25 and low estimates of $2.13.
Analysts are recommending an EPS of between $9.05 and $8.79 for the fiscal current year, implying an average EPS of $8.93. EPS for the following year is $9.61, with 25.0 analysts recommending between $10.27 and $8.48.
Revenue Estimates
In the current quarter, 14 analysts expect revenue to total $17B. It ranges from a high estimate of $17.22B to a low estimate of $16.61B. As of the current estimate, Merck & Co Inc’s year-ago sales were $16.66BFor the next quarter, 14 analysts are estimating revenue of $16.28B. There is a high estimate of $16.5B for the next quarter, whereas the lowest estimate is $15.95B.
A total of 26 analysts have provided revenue estimates for MRK’s current fiscal year. The highest revenue estimate was $65.39B, while the lowest revenue estimate was $64.05B, resulting in an average revenue estimate of $64.71B. In the same quarter a year ago, actual revenue was $64.17BBased on 25 analysts’ estimates, the company’s revenue will be $67.9B in the next fiscal year. The high estimate is $70.88B and the low estimate is $65.5B.
